Compare iShares Global Clean Energy ETF (ICLN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs 10X Genomics Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.26 (market cap $2.27B), while 10X Genomics Inc trades at $78.76 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 4.4× iShares Global Clean Energy ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and 10X Genomics Inc for 92 Days on average.
| ICLN | TXG | |
|---|---|---|
Market Cap | $2.27B | $10.07B |
Volume | 6,845,064 | 5,657,286 |
52-Week High | $23.75 | $97.74 |
52-Week Low | $15.78 | $11.48 |
Typical Hold Time | 87 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's financial ratios are unavailable in the provided data, but recent news highlights its focus on global clean energy with 105 holdings and a 0.38% expense ratio. It faces volatility, with a 57.2% maximum drawdown noted in comparisons against traditional energy ETFs.
The outlook for ICLN is mixed; geopolitical tensions and global renewable energy investments provide tailwinds, but high volatility and competition from fossil fuel ETFs pose risks. Investors should weigh its growth potential against expense ratios and performance consistency in the evolving energy sector.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
